Back to Results
First PageMeta Content
Biology / Biologic / Pharmacology / TNF inhibitor / Mucositis / Biotechnology / Monoclonal antibodies / Medicine


Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease LEXINGTON, Mass. – February 14, 2012 – Avaxia Biologics, Inc., a privately-held biotech company
Add to Reading List

Document Date: 2014-02-06 00:38:24

Open Document

File Size: 92,07 KB

Share Result on Facebook

City

LEXINGTON / /

Company

Smart Cells / Cannuflow / Merck / Avaxia Biologics Inc. / Medica Venture Partners / Launchpad Venture Group / Wadsworth Medical / Endosurgery Boston Scientific Corporation / Boston Scientific / Cool Systems / /

Country

United States / United Kingdom / /

Currency

USD / /

Event

Employment Change / Funding / FDA Phase / Reorganization / /

Facility

Massachusetts Life Sciences Center / Harbor Angels / Beacon Angels / /

IndustryTerm

investor network / pharmaceutical industry / /

MedicalCondition

celiac disease / inflammatory bowel disease / important disease / Inflammatory Bowel Disease LEXINGTON / GI Acute Radiation Syndrome / metabolic diseases / oral mucositis / diabetes / obesity / both diseases / /

MedicalTreatment

antibody therapy / radiation / /

Organization

Royal Society of Medicine / Boston Harbor Angels and Launchpad Venture Group / Boston Harbor Angels / Biomedical Advanced Research and Development Authority / Massachusetts Life Sciences Center / /

Person

Jonathan Fleming / Barbara Fox / Henry Kay / /

Position

CEO / Group Vice President / board member / member of the board / Group Vice President of New Market Development / Strategic Planning / /

Product

AVX-470 / advance / /

ProvinceOrState

Rhode Island / Massachusetts / /

Region

New England / /

Technology

Radiation / Antibodies / /

URL

www.avaxiabiologics.com / /

SocialTag